Menu
  • Join
  • Login
  • Contact
 

Search abstracts


THE USAGE EVALUATION OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN A LOCAL HOSPITAL OF TAIWAN

  • At: 2015 FIP Congress in Düsseldorf (Germany)
  • Type: Poster
  • By: CHANG, Hsiu-Mei (Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, pharmacy department, Kaohsiung City, China Taiwan)
  • Co-author(s): Hsiu-Mei Chang
  • Abstract:

    Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is orally used in diabetes. It was approved by FDA in 2006 to control blood sugar in patients with type-2 diabetes mellitus (T2DM). The usage has gradually increased since 2010 started in our hospital.Due to its high cost, Sitagliptin has become the second highest annual cost of oral medication..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses